Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
At a press conference at SABCS 2014, Prof Robertson discusses the results of the phase II FIRST trial, which compared overall survival with fulvestrant versus anastrozole as first-line treatment for patients with advanced hormone receptor-positive breast cancer:
Those patients who took fulvestrant lived longer than those who took anastrozole.
Read the news story or watch the interview here.
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Multiple Myeloma: evolving paradigm - Panel Discussion
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing Wisely for young women with breast cancer: Medical therapy
ESMO 2024: Latest in EGFR mutated NSCLC
Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC
Breastfeeding after breast cancer is safe
Neo-adjuvant therapy for different cancers in the Philippines